User profiles for Paari Murguan
Paari MuruganUniversity of Minnesota Verified email at umn.edu Cited by 1671 |
Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder
Purpose To provide a comprehensive update of the joint consultation of the International
Consultation on Urological Diseases (ICUD) for the diagnosis and management of non-…
Consultation on Urological Diseases (ICUD) for the diagnosis and management of non-…
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma
…, EJ Pietzak, JP Sfakianos, A Bagrodia, P Murugan… - Clinical Cancer …, 2019 - AACR
Purpose: To investigate genomic differences between urothelial carcinomas of the upper
tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally …
tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of temporally …
Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing …
…, DJ Einstein, CB Dechet, WT Lowrance, PJ Murugan… - 2020 - ascopubs.org
439 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) in MIBC improves
survival which correlates with pathologic response (PaR) at radical cystectomy (RC). The …
survival which correlates with pathologic response (PaR) at radical cystectomy (RC). The …
[HTML][HTML] Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: a combination panel-based approach with a brief …
P Murugan, N Siddaraju, S Habeebullah… - Indian journal of …, 2009 - journals.lww.com
Background: The prognostic and therapeutic significance of differentiating adenocarcinoma
(AC) from reactive mesothelium (RM) in effusions cannot be overemphasized. To avoid …
(AC) from reactive mesothelium (RM) in effusions cannot be overemphasized. To avoid …
Molecular characterization of neuroendocrine-like bladder cancer
…, S Gupta, P Grivas, KW Mouw, P Murugan… - Clinical cancer …, 2019 - AACR
Purpose: Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant.
Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) …
Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) …
3D printed organ models with physical properties of tissue and integrated sensors
The design and development of novel methodologies and customized materials to fabricate
patient‐specific 3D printed organ models with integrated sensing capabilities can yield …
patient‐specific 3D printed organ models with integrated sensing capabilities can yield …
Five new cases of primary renal carcinoid tumor: case reports and literature review
Carcinoid tumors, a slow-growing NET, most commonly arise in the gastrointestinal tract (73.7%),
followed by the bronchopulmonary system (25.1%), and least commonly in the …
followed by the bronchopulmonary system (25.1%), and least commonly in the …
Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases
The evolving classification of rhabdomyosarcoma (RMS) now includes spindle cell RMS (SRMS).
Bone/soft tissue SRMS often harbor TFCP2, or less often MEIS1 rearrangements. We …
Bone/soft tissue SRMS often harbor TFCP2, or less often MEIS1 rearrangements. We …
Biomonitoring DNA adducts of cooked meat carcinogens in human prostate by nano liquid chromatography–high resolution tandem mass spectrometry: identification …
…, PW Villalta, S Krishna, R Tejpaul, P Murugan… - Analytical …, 2016 - ACS Publications
Epidemiologic studies have reported an association between frequent consumption of well-done
cooked meats and prostate cancer risk. However, unambiguous physiochemical …
cooked meats and prostate cancer risk. However, unambiguous physiochemical …
[HTML][HTML] Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Endocrine therapies for prostate cancer inhibit the androgen receptor (AR) transcription
factor. In most cases, AR activity resumes during therapy and drives progression to castration-…
factor. In most cases, AR activity resumes during therapy and drives progression to castration-…